Seeking Alpha

Momenta Pharmaceuticals (MNTA +0.6%) gains on a solid Q4 earnings beat, but losses continue to...

Momenta Pharmaceuticals (MNTA +0.6%) gains on a solid Q4 earnings beat, but losses continue to widen and total revenue declined by 57% Y/Y. Total collaboration revenue was $12.7M, down from $29.5M a year prior due to declining enoxaparin sales. The company reafirms guidance going forward, noting that it expects total operating expenses to average $30M per quarter for 2013.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs